Franck F Lepifre

This inventor holds 12 USPTO granted patents, plus 4 CIPO patents and 3 EPO patents. Top assignees: Merck Patent Gmbh, Metabrain Research, Biophytis. Active years: 2012-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Franck F Lepifre. Retrieved from https://idiyas.com/inventor/franck-f-lepifre

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 66.7

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 27(Granted Patents)

Location History:

Longjumeau, FR (2012 - 2014)
Saclay, FR (2016 - 2019)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

Université Pierre Et Marie Curie (Paris 6)

patents

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10350184 - Derivatives used in the treatment of muscle atrophy (2019-07-16),

2. 10316056 - Chemical compounds and use thereof for improving muscular quality (2019-06-11),

3. 9938315 - Chemical compounds and use thereof for improving muscular quality (2018-04-10),

4. 9777015 - Useful thiophene derivatives in the treatment of diabetes (2017-10-03),

5. 9381191 - Imidazopyridine derivatives useful in treating diabetes (2016-07-05),

6. 9365584 - Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof (2016-06-14),

7. 9284329 - Thienopyridone derivatives useful as activators of AMPK (2016-03-15),

8. 8674097 - Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase (2014-03-18),

9. 8604202 - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators (2013-12-10),

10. 8563729 - Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators (2013-10-22),

11. 8486964 - Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors (2013-07-16),

12. 8329698 - Quinoxalinedione derivatives which are activators of AMPK-activated protein kinase (2012-12-11),

Title: Franck F Lepifre: Innovator in Muscle Health

Introduction

Franck F Lepifre is a notable inventor based in Saclay, France, recognized for his contributions to the field of muscle health. With a total of 12 patents to his name, he has made significant strides in developing therapeutic solutions aimed at improving muscular quality and preventing muscle atrophy.

Latest Patents

Among his latest patents, one focuses on derivatives used in the treatment of muscle atrophy. This invention involves oxime and alkoxy derivatives that serve as medicaments for treating and preventing muscle atrophy in mammals. It aims to promote muscle growth, increase muscle mass and quality, and prevent age-related symptoms such as sarcopenia. Another significant patent involves chemical compounds designed to improve muscular quality in mammals, particularly targeting sarcopenic obesity and its associated complications. This method not only addresses muscle quality in sarcopenic mammals but also aims to treat obesity and related pathologies, including type 2 diabetes and metabolic syndrome.

Career Highlights

Franck has worked with prominent companies such as Merck Patent GmbH and Metabrain Research, where he has applied his expertise in developing innovative solutions for muscle health. His work has been instrumental in advancing therapeutic approaches that address critical health issues related to muscle deterioration.

Collaborations

Throughout his career, Franck has collaborated with esteemed colleagues, including Christine G Charon and Daniel Cravo, contributing to a rich exchange of ideas and innovations in the field.

Conclusion

Franck F Lepifre's work exemplifies the intersection of innovation and health, particularly in the realm of muscle quality and atrophy prevention. His patents and collaborations reflect a commitment to enhancing the well-being of mammals through scientific advancements.

Profile summary based on public USPTO records.